Tandem Meetings 2023 | Predictive factors for HLH toxicity in patients with B-ALL treated with tisa-cel
Kevin McNerney, MD, MSc, Johns Hopkins All Children’s Hospital, St. Petersburg, FL, comments on the results of a study that investigated factors associated with hemophagocytic lymphohistiocytosis (HLH)-like toxicities in patients with B-cell acute lymphoblastic leukemia (B-ALL) treated with tisagenlecleucel (tisa-cel). The study identified high disease burden as well as severe neutropenia as the two main predictive factors for HLH-like toxicity and created a model to identify patients at a high risk of developing these toxicities prior to CAR-T infusion. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
